These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18555946)

  • 1. Initiating antidiabetic drug therapy.
    Kostenbauder HB
    Clin Ther; 2008 May; 30(5):986; author reply 986-7. PubMed ID: 18555946
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007; 29 Spec No():1306-15. PubMed ID: 18046930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?
    Hsu JC; Ross-Degnan D; Wagner AK; Zhang F; Lu CY
    Clin Ther; 2015 Jul; 37(7):1420-1432.e1. PubMed ID: 25976425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
    Home P; Bagust A; Taylor M; Ambery P; Mendes da Costa S
    Pharmacoeconomics; 2007; 25(9):801-2; author reply 802-5. PubMed ID: 17803338
    [No Abstract]   [Full Text] [Related]  

  • 7. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
    Tunis SL; Minshall ME; St Charles M; Pandya BJ; Baran RW
    Curr Med Res Opin; 2008 Nov; 24(11):3085-96. PubMed ID: 18826750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis.
    Balkrishnan R; Rajagopalan R; Shenolikar RA; Camacho FT; Whitmire JT; Anderson RT
    Curr Med Res Opin; 2004 Oct; 20(10):1633-40. PubMed ID: 15462696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
    Breunig IM; Shaya FT; McPherson ML; Snitker S
    J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis.
    Shenolikar RA; Balkrishnan R; Camacho FT; Whitmire JT; Anderson RT
    Clin Ther; 2006 Aug; 28(8):1199-1207. PubMed ID: 16982297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
    Hansen RA; Farley JF; Droege M; Maciejewski ML
    Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
    Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
    Valentine WJ; Tucker D; Palmer AJ; Minshall ME; Foos V; Silberman C;
    Value Health; 2009; 12(1):1-9. PubMed ID: 18657104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al.
    Brunzell JD
    Diabetes Care; 2005 Dec; 28(12):2984-5; author reply 2985-6. PubMed ID: 16331869
    [No Abstract]   [Full Text] [Related]  

  • 17. The value equation for rosiglitazone and pioglitazone in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
    [No Abstract]   [Full Text] [Related]  

  • 18. Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes.
    Palmer AJ; Currie CJ
    Pharmacoeconomics; 2006; 24(9):927-9; author reply 929-35. PubMed ID: 16942126
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
    Doggrell SA
    Expert Opin Pharmacother; 2008 Feb; 9(3):405-20. PubMed ID: 18220491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.